2216
ARDS is rarely associated with rituximab infusion for lympho-proliferative disorders, but it should be considered by those administering rituximab, especially when a patient develops severe pulmonary symptoms soon after infusion.
 adverse event: after 
Please tell me event type and its trigger word from given type options. Output format is "type: trigger".  Option: adverse event, potential therapeutic event 
Text: {0} 
Answer:
 adverse event: after 